Substance / Medication

Canakinumab

Overview

Active Ingredient
canakinumab
RxNorm CUI
853491
Labeler: Novartis Pharmaceuticals CorporationUpdated: 2025-06-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

[see Warnings and Precautions (5.3) Adverse Reactions (6.1)] Confirmed hypersensitivity to canakinumab or to any of the excipientsand.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Off-label use of canakinumab in pediatric rheumatology and rare diseases.
Del Giudice Emanuela, Sota Jurgen, Orlando Francesca et al. · Front Med (Lausanne) · 2022
PMID: 36330067Meta-AnalysisFull text (PMC)
The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis.
Ao Guangyu, Wang Yushu, Li Toni et al. · J Infect · 2022
PMID: 35301014Meta-AnalysisFull text (PMC)
Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review.
Cota-Arce Julián M, Cota Jonhatan, De León-Nava Marco A et al. · Semin Arthritis Rheum · 2021
PMID: 34493394Meta-Analysis
Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
Betrains A, Staels F, Vanderschueren S · Semin Arthritis Rheum · 2020
PMID: 32502728Meta-Analysis
Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial.
Orkaby Ariela R, Thomson Aerin, MacFadyen Jean et al. · Aging Cell · 2024
PMID: 37927208RCTFull text (PMC)
Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.
Woo Janghee, Zhai Tingting, Yang Fang et al. · Cancer Prev Res (Phila) · 2024
PMID: 38701435RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Canakinumab (substance)
SNOMED CT
698091001
UMLS CUI
C2718773
RxNorm CUI
853491
Labeler
Novartis Pharmaceuticals Corporation

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.